HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 316 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,598 | +5.9% | 68 | 0.0% | 0.00% | – |
| Q2 2023 | $2,453 | -15.5% | 68 | -10.5% | 0.00% | -100.0% |
| Q1 2023 | $2,902 | -32.9% | 76 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $4,324 | +44.1% | 76 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $3,000 | 0.0% | 76 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $3,000 | 0.0% | 76 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $3,000 | 0.0% | 76 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $3,000 | +200.0% | 76 | +192.3% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 26 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | 0.0% | 26 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | -50.0% | 26 | -43.5% | 0.00% | – |
| Q4 2020 | $2,000 | +100.0% | 46 | +100.0% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 23 | 0.0% | 0.00% | – |
| Q2 2020 | $1,000 | – | 23 | +27.8% | 0.00% | – |
| Q1 2020 | $0 | – | 18 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | – | 18 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |